WASHINGTON, DC - Transcatheter aortic valve replacement (TAVR) with the use of the TELLTALE Leaflet Modification System prevents coronary obstruction in patients who have native aortic stenosis (AS) or bioprosthetic valve failure with high-risk anatomy, a new study shows.